AstraZeneca to Invest $50 Billion in US Manufacturing
AstraZeneca recently announced $50 billion of investment in the US by 2030. This investment is expected to create tens of thousands of new, highly skilled jobs nationwide.
Pharma
Abzena Appoints Geoffrey M. Glass as Chief Executive Officer
Abzena, an end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, recently announced that Geoffrey M. Glass has been appointed Chief Executive Officer, effective immediately.
Sanner Opens its First US Production Facility in North Carolina
Sanner, a provider of high-quality healthcare packaging and drug delivery solutions, officially opened its first US-based production facility in Greensboro, North Carolina.
ISPE Good Practice Guide: Validation 4.0
The Validation 4.0 Guide provides a comprehensive approach to ensuring product quality and patient safety throughout a pharmaceutical product's lifecycle.
Roquette Appoints Thierry Fournier as CEO
Roquette Appoints Thierry Fournier as Chief Executive Officer
MSD to Acquire Verona Pharma for $10 Billion
MSD, known as Merck & Co. in the US and Canada, recently announced it will acquire Verona Pharma, a biopharmaceutical company focused on respiratory diseases, for approximately $10 billion.
Pace Life Sciences Expands Sterile Filling Capabilities
Pace Life Sciences, a US-based contract research, development, and manufacturing organization (CRDMO), is remodeling and expanding its Salem, NH site for aseptic fill-finish processing.
AbbVie to Acquire Capstan Therapeutics for $2 Billion
AbbVie has announced it will acquire Capstan Therapeutics, a clinical-stage biotechnology company focused on advancing in vivo cell engineering through RNA delivery using targeted lipid nanoparticles (tLNPs).
Axplora Announces €35 Million Expansion at Farmabios
Axplora to expand its Farmabios site in Gropello Cairoli, Italy, with a €35 million investment.
Pharma Service Provider Vetter Establishes New Site in Chicago
Vetter broke ground for the start of construction of its new clinical site in Des Plaines, Illinois, US on June 26.
IMCD Acquires Indian Pharma Supplier Trichem
IMCD, a global partner for the distribution and formulation of speciality chemicals and ingredients, has acquired Trichem, an Indian pharmaceutical supplier.
Celltrion Opens UK Headquarters in Uxbridge
Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK.
Mabion Launches €500,000 Oncology Services Contest
Mabion, a biotech-focused CDMO offering end-to-end services, has announced the launch of a €500,000 oncology services contest at BIO International Convention 2025.
Schott Pharma Invests in Sterile Cartridge Production
Schott Pharma is investing more than €100 million in its existing site in Lukácsháza, Hungary, to expand its capacity for sterile ready-to-use (RTU) cartridges.
Resilience Will Close 6 of its 10 Plants
Resilience recently shared that capacity expansions have exceeded current industry demand. As a result, Resilience has begun consolidating its operations and streamlining its business strategy.
Brenntag Specialties Acquires Mcepharma
Brenntag recently announced the acquisition of Mcepharma to strengthen Brenntag’s capabilities across the entire pharmaceutical and biopharmaceutical value chain.
Sanofi to Acquire Blueprint Medicines
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology.
Sterling Pharma Solutions and Kivu Bioscience Enter Manufacturing Pact
Sterling Pharma Solutions to produce an antibody-drug conjugate (ADC) candidate for Kivu Bioscience.
Sanofi to Acquire Vigil Neuroscience
Sanofi to acquire Vigil Neuroscience, a clinical-stage biotech focused on therapies for neurodegenerative diseases.
Curia Announces Expansions to Global Network of Sterile Fill-Finish Sites
Curia, a CDMO, recently shared expansion plans for facilities in Glasgow, UK, and Albuquerque, NM, US.
Pharma Outlook 2025
The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.
“Access to Talent is a Crucial Factor”
In an interview with CHEManager, Edgardo Hernandez, President of Lilly Manufacturing, explains the strategy behind the ambitious investment project.
PCI Pharma Services Acquires Ajinomoto Althea
PCI Pharma Services has completed its acquisition of Ajinomoto Althea, a CDMO subsidiary of Ajinomoto.
Roquette Acquires IFF Pharma, Reorganizes into Two Business Groups
Roquette completes IFF Pharma Solutions acquisition and unveils new structure for global growth and innovation.
Cyprumed and MSD Enter Licensing Agreement for Oral Peptide Therapeutics
MSD receives a non-exclusive license for Cyprumed's drug delivery technology for developing oral peptide therapeutics.
Austria: A Hotspot for Life Sciences
An Attractive and Highly Sought-after Business Location
The life sciences sector, encompassing biotechnology, pharmaceuticals and medical technology, is developing rapidly in Austria.
Increasing Gap in Biotech Venture Funding
Consulting firm BCG has evaluated the effectiveness of biotech innovation centers in Europe and the USA. Adolphs explains what is lacking in Germany in particular.
Europe’s Biotech Cluster Powerhouses
Cambridge, Leiden, Heidelberg or Paris - many European countries have biotechnology clusters in which scientific expertise meets a well-developed infrastructure, committed entrepreneurship and attractive financing opportunities. A subjective look at the best.
Productivity in Biopharma Research Picks Up
Technological developments in the pharmaceutical and biotech industry are reflected in increased funding, higher R&D productivity and more product launches. However, the general conditions remain challenging. Incremental change won’t be enough to deliver the results that the market and patients demand, warn industry experts.
The Success Story of Biosimilars
With their triumphant advance, biosimilars are also setting in motion the usual market mechanisms. Biopharma interest groups warn against the automatic substitution of originator drugs.
Expanding Expertise in Highly-Potent APIs
After acquiring the two Catalonian sites in Barberà del Vallès and El Masnou about two years ago, Siegfried is now significantly expanding its expertise in the production of complex Drug Products containing Highly-Potent APIs (HPAPIs). In addition, the company has opened a new development center for oral solid dosage forms with active ingredients and HPAPIs as well as for ophthalmic sterile products. This not only strengthens Siegfried's position in the area of drug products, but also its global network and international competitiveness.
Small Substances with Big Effects
The market for APIs is expanding significantly. Experts predict annual growth rates between 4.5 and 7.6 percent by 2029. There are plenty of good reasons for this: Chronic diseases are on the rise - and with them the need for medicines and active ingredients. In addition, the economic upswing in several emerging countries means that more people can afford novel medicines. APIs are also benefiting from the trend toward personalized medicine and the growing understanding of diseases. Meanwhile, API developers and manufacturers are working on increasingly sophisticated methods to better handle these delicate substances.
